BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with laboratory-confirmed acute viral infection. The Bioxyytran Trial reports complete elimination of viral load in 100% of patients at day 7 versus placebo (p=.001). The completed Phase 2 clinical study was a randomized, double-blind, placebo-controlled, ...

Core Viewpoint - The outlook on Mesoblast Limited (MESO) is bullish due to the U.S. commercial launch of Ryoncil for pediatric steroid-refractory acute graft versus host disease, indicating a transition from a development-stage biotech to a more established entity [1] Group 1: Company Analysis - Mesoblast Limited is positioned in a high-growth sector, focusing on innovative solutions that are expected to drive substantial returns [1] - The company is leveraging disruptive technologies to enhance its market presence and growth potential [1] Group 2: Market Trends - The investment strategy emphasizes a mix of fundamental analysis and future trend predictions, highlighting the importance of innovation in achieving growth [1]

Market Overview - The Australian Sharemarket saw a significant rally, with the S&P/ASX 200 closing at 9,014.80, up 147.40 points or 1.66%, marking a new 50-day high and the strongest close since late October 2025 [1][8] - The index has gained 0.97% over the last five days and is currently 1.10% off its 52-week high [2] Top Performers - AUSSIE BROADBAND LIMITED and AGL ENERGY LIMITED were the top performers, rising 14.79% and 11.75%, respectively [2][8] - Commonwealth Bank of Australia (CBA) rose 6.8% after reporting record first-half cash earnings, contributing to a 3.8% increase in heavyweight financials [3][8] Notable Stock Movements - Evolution Mining Limited (EVN) gained $1.300 to close at $16.280, an increase of 8.678% [6] - James Hardie Industries plc (JHX) advanced from $3.630 to $36.870, up 10.920% [8] - Domino's Pizza Enterprises shares rose 2.9% following the appointment of former McDonald's executive Andrew Gregory as CEO [9] Decliners - CSL Limited experienced the steepest decline, falling from $20.200 to $163.440, a drop of 11.000% [6][8] - Biotech major CSL slumped 18.2% to an eight-year low due to CEO Paul McKenzie's departure and a significant drop in half-year profit, impacting healthcare stocks which fell as much as 6.2% [8][9] - ResMed Inc. (RMD) slipped $1.760 to $36.790, down 4.566% [6]

Core Viewpoint - CSL Limited experienced a significant drop in share price, falling over 12% due to weaker half-year earnings and a sudden CEO exit, marking a shift in investor sentiment towards the company [1][5]. Financial Performance - CSL reported total revenue of US$8.3 billion for the half, a 4% decline in constant currency terms [2]. - Underlying NPATA was US$1.9 billion, reflecting a 7% decrease compared to the prior period [2]. - Reported net profit (NPAT) plummeted 81% to US$401 million, impacted by one-off restructuring costs and asset impairments totaling approximately US$1.1 billion [2]. Dividends and Cash Flow - The interim dividend remained unchanged at US$1.30 per share [3]. - Cash flow from operations increased by 3% to US$1.3 billion [3]. - Management expanded the share buyback program from US$500 million to US$750 million [3]. Business Challenges - The earnings results were negatively affected by government policy changes, restructuring costs, and impairments, particularly related to CSL Vifor and Seqirus [4]. - While some business segments are stabilizing, core areas continue to face pressure, indicating a deeper reset rather than a simple cyclical slowdown [4]. Market Reaction - The sharp market reaction was driven not only by the 7% profit decline but also by the unexpected leadership change and falling revenue, which led investors to reassess growth expectations for CSL [5]. - The market is seeking clearer evidence of operational momentum and improved margins, as well as leadership stability following recent turbulence [9]. Long-term Outlook - Despite current challenges, CSL remains a global biotechnology leader with strong intellectual property and a robust plasma infrastructure, suggesting that long-term demand drivers are still intact [7].

Company Overview - Robinhood's fourth quarter revenue missed expectations, leading to an almost 8% decline in after-hours trading [1] - The stock was already down about 40% from its all-time high in October, raising concerns about its performance during the current crypto downturn [4] Financial Performance - Key metrics showed deceleration, particularly in net deposit growth, which continued to decline into January [2] - Despite the topline miss, management's commentary on future business growth and transaction volumes was constructive, indicating a decent outlook [3] Crypto Market Impact - Crypto revenue has decreased from over 20% to an expected near 10% of total business, with a potential 50% haircut to current trading volumes during a crypto winter [6] - This scenario would only result in a manageable 10% hit to Robinhood's EBITDA [6] Business Diversification - Robinhood is better positioned during the current crypto downturn due to its diversified product lineup, including a significant increase in net interest income and new offerings like retirement accounts and banking products [9][10] - The company is evolving into a more comprehensive financial app, which enhances its resilience compared to previous downturns [8] Options Trading Growth - Options trading, which constitutes about 25% of Robinhood's revenue, is expected to see significant growth, potentially up to 40% due to increased penetration and new product offerings [12][14] - The options market is less cyclical, allowing for trading in both up and down markets, which supports long-term growth for Robinhood [13] Prediction Markets - Robinhood's entry into prediction markets is seen as a potential growth area, leveraging its strong distribution capabilities despite increasing competition [15] - The company has announced a partnership that enhances its control over economics and product innovation in this space [16]

Core Insights - Upstream Bio, Inc. is set to report top-line results from the Phase 2 VALIANT trial of verekitug, a treatment targeting the TSLP receptor, on February 11, 2026 [1][2] Group 1: Company Overview - Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing verekitug, the only known antagonist in clinical development targeting the TSLP receptor, which is involved in inflammatory responses [4] - Upstream Bio aims to address significant unmet needs in patients underserved by current standard care through its development of verekitug [4] Group 2: VALIANT Trial Details - The VALIANT trial is a Phase 2 global, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of verekitug in 478 patients with severe asthma [2] - Participants in the trial were divided into four groups, receiving either 100 mg or 400 mg of verekitug every 24 weeks, 100 mg every 12 weeks, or a placebo, administered subcutaneously [2]

As filed with the U.S. Securities and Exchange Commission on February 10, 2026. Registration No. 333-292285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– Brookline Capital Acquisition Corp II (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––––––––––––––––– | Cayman Islands | 6770 | N/A | | - ...

Core Insights - Septerna, Inc. has granted an inducement award to its Chief Legal Officer, Mark A. Wilson, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company's 2026 Inducement Plan [1][2] Group 1: Stock Option Details - The stock option has an exercise price of $25.41 per share, which is equal to Septerna's closing share price on February 6, 2026 [2] - The stock option will vest over four years, with 25% of the shares vesting on the one-year anniversary and the remaining 75% vesting in equal monthly installments over 36 months, contingent on Mr. Wilson's continuous employment [2] Group 2: Company Overview - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, aiming to address significant unmet medical needs [3] - The company utilizes its proprietary Native Complex Platform to develop a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [3]

Market Overview - The US market is experiencing modest gains, with the Dow up approximately 350 points and the S&P 500 attempting to reach a new record close [1] - Consumer discretionary stocks are performing well despite retail sales data showing no growth for the holiday season, which was below the expected increase of 0.4% [1] - Spotify shares surged nearly 17% following strong subscriber growth and improved margins, marking its best gain in about a year [1] Retail Sales and Consumer Behavior - December retail sales data indicated flat year-over-year sales, contrasting with a 6.4% increase in holiday spending across all generations [1][2] - High-income households (earning $125,000 or more) increased their holiday spending by 29%, while mid and low-income cohorts reduced spending by about 4% [2] - The K-shaped economy is evident, with wealthier consumers driving spending while lower-income consumers focus on essentials [2] Company Earnings and Forecasts - CVS reported a strong fourth quarter, with revenue from healthcare benefits rising 10% to approximately $36 billion and pharmacy services revenue increasing by 9% to about $51 billion [5] - CVS's profit guidance for 2026 is set between $7 and $7.20 per share, with a cash forecast of $9 billion for the year [5][6] - Coca-Cola's shares fell over 1% after a disappointing forecast, while S&P Global's shares dropped 8% due to a weak outlook [1] Streaming Industry Insights - Spotify's record user growth is attributed to innovative marketing strategies like its Wrapped campaign and curated playlists [1][45] - The company aims to maintain its market dominance by continuously engaging new users and enhancing its service offerings [45] Biotech Sector Developments - The biotech industry is expected to see an increase in M&A activity, with companies like Halosime actively acquiring startups to enhance drug delivery technologies [4] - Halosime's recent acquisitions focus on subcutaneous drug delivery, which could transform patient care by reducing the need for lengthy infusion treatments [4] Travel and Hospitality Sector - Marriott reported strong demand for travel, particularly in the luxury segment, despite challenges from government shutdowns affecting business travel [27][29] - The company anticipates continued growth in revenue per available room (RevPAR) and has a robust pipeline of new hotel openings [29]

Core Viewpoint - Exelixis, Inc. is highlighted as a promising healthcare stock under $50, with a recent price target revision by Barclays indicating a positive outlook for the company [1]. Group 1: Financial Updates - Barclays revised the price target for Exelixis, Inc. to $44 from $41 while maintaining an Equal Weight rating [1]. Group 2: Drug Development - Exelixis announced the acceptance of its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for treating adult patients with metastatic colorectal cancer [2]. - The FDA has assigned a standard review for zanzalintinib, with a target action date of December 3, 2026 [3]. - Dana T. Aftab, Ph.D., emphasized the potential of zanzalintinib to provide a novel mechanism of action for previously treated metastatic colorectal cancer patients if approved [3]. Group 3: Company Overview - Exelixis, Inc. focuses on discovering, developing, and commercializing new medicines for difficult-to-treat cancers, with a product portfolio that includes cabometyx, cometriq, and cotellic [4].